“Profiling of host response to immunotherapy addresses a major challenge in oncology today – understanding why treatment helps some patients but not others,” said Dr. Ofer Sharon, CEO of OncoHost. “By combining OncoHost’s proprietary technology with proteomic analysis (the large-scale study of proteins), we are able to predict how individual patients may respond to treatment. This is the first step towards developing successful personalized cancer treatment plans.”
Read more here.